INS and metabolic dysfunction-associated steatohepatitis: However, our subgroup analyses showed that NASH patients who underwent both lifestyle changes and TZD therapy experienced a significantly greater reduction in fasting insulin level than that in the control patients, whereas patients treated with TZDs alone did not experience a significantly greater reduction in fasting insulin level than that in patients who received a placebo.